Aethox Therapeutics Analysis
What is Aethox Therapeutics?
Aethox Therapeutics is a preclinical-stage UK-based spin-out from King’s College London focused on disrupting cancer's immune defenses. The company has identified a key mechanism where tumors use macrophages to shield themselves from chemotherapy. Small molecule inhibitors are being developed to block this process, enhancing treatment efficacy. The first-in-class anti-cancer drug is being prepared for a Phase 1 clinical trial in patients with solid tumors.
Location
London, United Kingdom
Employees
1-10
Founded
2025
Product Features & Capabilities
- Small molecule inhibitors targeting macrophage-mediated tumor shielding
- Inhibitors designed to enhance chemotherapy effectiveness
- Preclinical development of first-in-class anti-cancer drug
Use Cases
Block macrophage-mediated immune shielding in solid tumors; Enhance chemotherapy effectiveness in patients with resistant cancers; Prepare first-in-class drug for Phase 1 trial in solid tumor patients; Develop inhibitors to counteract tumor immune evasion mechanisms; Target macrophage activity in preclinical cancer models
Other Considerations
Preclinical-stage; Spin-out from King’s College London; First-in-class anti-cancer drug in development; Targeting macrophage-mediated tumor shielding; Preparing for Phase 1 trial in solid tumors
See something that needs updating? Suggest edits to this profile.